

Patient, caregiver, and oncologist perceptions of cancer tripart assessment survey. The Fatigue Coalition

Seminars in Hematology

34, 4-12

Citation Report

#	ARTICLE	IF	CITATIONS
1	Quality of life and psychosocial adjustment in patients with myelodysplastic syndromes. <i>Leukemia Research</i> , 1998, 22, S41-S47.	0.4	26
2	Current clinical trial design issues in hormone-refractory prostate carcinoma. , 1998, 82, 2093-2101.		21
3	Nurses' assessments of symptom occurrence and symptom distress in chemotherapy patients. <i>European Journal of Oncology Nursing</i> , 1998, 2, 14-26.	0.9	20
4	Anemia and fatigue in cancer patients. <i>Journal of Oncology Pharmacy Practice</i> , 1998, 4, S5-S11.	0.5	0
5	Cancer-Related Fatigue: Guidelines for Evaluation and Management. <i>Oncologist</i> , 1999, 4, 1-10.	1.9	339
6	The problem of weakness in patients with advanced cancer. <i>International Journal of Palliative Nursing</i> , 1999, 5, 6-12.	0.2	4
7	Pain, Fatigue, and Sleep Disturbances in Oncology Outpatients Receiving Radiation Therapy for Bone Metastasis. <i>Journal of Pain and Symptom Management</i> , 1999, 17, 320-332.	0.6	300
8	Fatigue in Women Receiving Adjuvant Chemotherapy for Breast Cancer. <i>Journal of Pain and Symptom Management</i> , 1999, 18, 233-242.	0.6	311
9	Fatigue in an Older Population. <i>Journal of the American Geriatrics Society</i> , 2000, 48, 426-430.	1.3	136
10	Cancer-related fatigue: Inevitable, unimportant and untreatable? Results of a multi-centre patient survey. <i>Annals of Oncology</i> , 2000, 11, 971-976.	0.6	364
11	Symptom and quality of life survey of medical oncology patients at a Veterans Affairs medical center. , 2000, 88, 1175-1183.		280
12	Quality of life changes during conformal radiation therapy for prostate carcinoma. <i>Cancer</i> , 2000, 89, 1322-1328.	2.0	83
13	Effects of Multidrug Resistance Gene Expression in Acute Erythroleukemia. <i>Modern Pathology</i> , 2000, 13, 407-413.	2.9	16
14	Daily Fatigue Patterns and Effect of Exercise in Women with Breast Cancer. <i>Cancer Practice</i> , 2000, 8, 16-24.	0.8	200
15	Cancer-Related Fatigue. Suffering a Different Fatigue. <i>Cancer Practice</i> , 2000, 8, 87-95.	0.8	84
16	Developing a Community Program on Cancer Pain and Fatigue. <i>Cancer Practice</i> , 2000, 8, 187-194.	0.8	21
17	Immunophenotypic and Genotypic Markers of Follicular Center Cell Neoplasia in Diffuse Large B-Cell Lymphomas. <i>Modern Pathology</i> , 2000, 13, 1219-1231.	2.9	65
18	Cancer-Related Fatigue: An Immense Problem. <i>Oncologist</i> , 2000, 5, 350-352.	1.9	51

#	ARTICLE	IF	CITATIONS
19	Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition. <i>Oncologist</i> , 2000, 5, 353-360.	1.9	1,048
20	Consensus statement: Anemia in HIV infection—current trends, treatment options, and practice strategies. <i>Clinical Therapeutics</i> , 2000, 22, 1004-1020.	1.1	58
21	Fatigue in patients with prostate cancer receiving hormone therapy. <i>European Journal of Cancer</i> , 2000, 36, 1134-1141.	1.3	217
22	Recent progress in improving quality of life in cancer patients. <i>Pharmaceutical Medicine</i> , 2000, 14, 85-87.	0.4	1
23	“I don't have any energy”: The experience of fatigue in young adult survivors of childhood cancer. <i>European Journal of Oncology Nursing</i> , 2000, 4, 20-28.	0.9	57
24	Commentary. <i>European Journal of Oncology Nursing</i> , 2001, 5, 218-220.	0.9	1
25	Radiotherapy-related Fatigue: How to Assess and how to Treat the Symptom. A Commentary. <i>Tumori</i> , 2001, 87, 147-151.	0.6	22
26	Cancer-Related Fatigue. <i>American Journal of Nursing</i> , 2001, 101, 31-34.	0.2	2
27	Cancer-related anaemia requires higher doses of epoetin alfa than chronic renal failure replacement therapy. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 2289-2293.	0.4	2
28	Strategies for managing cancer-related fatigue syndrome. <i>Cancer</i> , 2001, 92, 988-997.	2.0	100
29	Fatigue management. <i>Cancer</i> , 2001, 92, 1699-1707.	2.0	114
30	A fatigue clinic in a comprehensive cancer center. <i>Cancer</i> , 2001, 92, 1708-1713.	2.0	26
31	Anemia and fatigue in cancer patients. <i>Cancer</i> , 2001, 92, 1719-1724.	2.0	41
32	Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. <i>British Journal of Cancer</i> , 2001, 84, 31-37.	2.9	90
33	Fatigue in Ambulatory Patients with Advanced Lung Cancer. <i>Journal of Pain and Symptom Management</i> , 2001, 22, 554-564.	0.6	137
34	I Get Tired for No Reason. <i>Journal of Pain and Symptom Management</i> , 2001, 22, 931-937.	0.6	69
35	DNA Topoisomerase III $\alpha$ in Multiple Myeloma: A Marker of Cell Proliferation and Not Drug Resistance. <i>Modern Pathology</i> , 2001, 14, 886-891.	2.9	22
36	Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. <i>British Journal of Cancer</i> , 2002, 87, 1341-1353.	2.9	116

#	ARTICLE	IF	CITATIONS
37	Managing Anemia in the Cancer Patient: Old Problems, Future Solutions. <i>Oncologist</i> , 2002, 7, 331-341.	1.9	32
38	The measurement, causes and effective management of cancer-related fatigue. <i>International Journal of Palliative Nursing</i> , 2002, 8, 120-128.	0.2	57
39	The impact of hemoglobin levels on fatigue and quality of life in cancer patients. <i>Annals of Oncology</i> , 2002, 13, 965-973.	0.6	128
40	Erythropoiesis and iron. <i>Best Practice and Research in Clinical Haematology</i> , 2002, 15, 399-409.	0.7	29
41	Management Options for Cancer Therapy-Related Anaemia. <i>Drug Safety</i> , 2002, 25, 525-535.	1.4	5
42	Benefits of Epoetin Alfa in Anemic Breast Cancer Patients Receiving Chemotherapy. <i>Clinical Breast Cancer</i> , 2002, 3, 45-51.	1.1	39
43	Increasing the visibility of patient fatigue. <i>Seminars in Oncology Nursing</i> , 2002, 18, 20-27.	0.7	4
44	Symptoms affecting quality of life in women with gynecologic cancer. <i>Seminars in Oncology Nursing</i> , 2002, 18, 223-230.	0.7	39
47	Managing Anemia in Patients with Chronic Kidney Disease or Cancer: Development and Role of Darbepoetin alfa. <i>Pharmacotherapy</i> , 2002, 22, 129S-132S.	1.2	3
48	Radiotherapy related fatigue: strategies and knowledge of the UK radiographer and nurse. <i>Radiography</i> , 2002, 8, 149-158.	1.1	1
49	Meaningful survival in lung cancer patients. <i>Seminars in Oncology</i> , 2002, 29, 125-131.	0.8	12
50	Preliminary Evaluation of a Clinical Syndrome Approach to Assessing Cancer-Related Fatigue. <i>Journal of Pain and Symptom Management</i> , 2002, 23, 406-416.	0.6	86
51	United States. <i>Journal of Pain and Symptom Management</i> , 2002, 24, 265-269.	0.6	10
52	Patient-Related Barriers to Fatigue Communication. <i>Journal of Pain and Symptom Management</i> , 2002, 24, 481-493.	0.6	119
53	Clinical relevance of fatigue levels in cancer patients at a Veterans Administration Medical Center. <i>Cancer</i> , 2002, 94, 2481-2489.	2.0	70
54	Changing patient perceptions of the side effects of cancer chemotherapy. <i>Cancer</i> , 2002, 95, 155-163.	2.0	385
55	Standards of care for anemia management in oncology. <i>Cancer</i> , 2002, 95, 613-623.	2.0	25
56	Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. <i>Cancer</i> , 2002, 95, 888-895.	2.0	398

#	ARTICLE	IF	CITATIONS
57	Cancer fatigue—more data, less information?. <i>Current Oncology Reports</i> , 2002, 4, 275-279.	1.8	3
58	Recurrent growth factor starvation promotes drug resistance in human leukaemic cells. <i>British Journal of Cancer</i> , 2002, 86, 292-300.	2.9	7
59	Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. <i>British Journal of Cancer</i> , 2002, 87, 268-276.	2.9	162
60	EPO's Alter Ego: Erythropoietin Has Multiple Actions. <i>Stem Cells</i> , 2002, 20, 485-492.	1.4	117
61	Antidepressant prescribing in community cancer care. <i>Supportive Care in Cancer</i> , 2003, 11, 278-285.	1.0	84
62	Impact of Long-Acting Growth Factors on Practice Dynamics and Patient Satisfaction. <i>Pharmacotherapy</i> , 2003, 23, 101S-109S.	1.2	33
63	Fatigue in ovarian carcinoma patients. <i>Cancer</i> , 2003, 97, 1564-1572.	2.0	90
64	Once-weekly dosing of epoetin- $\alpha$ increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. <i>Cancer</i> , 2003, 98, 1072-1079.	2.0	98
65	Cancer-related fatigue. <i>Cancer</i> , 2003, 98, 1786-1801.	2.0	439
66	Fatigue and aging. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 48, S57-S64.	2.0	39
67	Cancer-related fatigue - a difference of opinion? Results of a multicentre survey of healthcare professionals, patients and caregivers. <i>European Journal of Cancer Care</i> , 2003, 12, 20-27.	0.7	64
68	A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. <i>British Journal of Cancer</i> , 2003, 88, 1851-1858.	2.9	72
69	Anemia in Lung Cancer: Clinical Impact and Management. <i>Clinical Lung Cancer</i> , 2003, 5, 90-97.	1.1	33
70	Epoetin Alfa Therapy for Patients with Hematologic Malignancies and Mild Anemia. <i>Clinical Lymphoma and Myeloma</i> , 2003, 4, S13-S17.	2.1	4
71	Fatigue in adolescents with and following a cancer diagnosis. <i>European Journal of Cancer</i> , 2003, 39, 2671-2680.	1.3	30
72	Quality of life in patients receiving treatment for gynecologic malignancies: Special considerations for patient care. <i>International Journal of Gynecology and Obstetrics</i> , 2003, 83, 211-229.	1.0	31
73	Assessment and management of cancer-related fatigue in adults. <i>Lancet, The</i> , 2003, 362, 640-650.	6.3	464
74	A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. <i>Clinical Therapeutics</i> , 2003, 25, 2781-2796.	1.1	55

#	ARTICLE	IF	CITATIONS
75	Current management of fatigue and anemia in patients with cancer. <i>Seminars in Oncology Nursing</i> , 2003, 19, 36-41.	0.7	23
76	Chemotherapy-related cognitive dysfunction in breast cancer. <i>Seminars in Oncology Nursing</i> , 2003, 19, 17-24.	0.7	35
77	Managing complications in cancer: identifying and responding to the patient's perspective. <i>Seminars in Oncology Nursing</i> , 2003, 19, 1-9.	0.7	29
78	Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. <i>European Journal of Cancer</i> , 2003, 39, 335-345.	1.3	83
79	Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. <i>European Journal of Cancer</i> , 2003, 39, 2026-2034.	1.3	132
80	Baseline and Early Treatment Factors are not Clinically Useful for Predicting Individual Response to Erythropoietin in Anemic Cancer Patients. <i>Oncologist</i> , 2003, 8, 99-107.	1.9	45
81	Recognising pain as a component of symptom clusters: A means of informing the nursing management of symptoms and side-effects. <i>Journal of Research in Nursing</i> , 2003, 8, 354-363.	0.4	2
82	T-Cell Homeostasis in Breast Cancer Survivors With Persistent Fatigue. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1165-1168.	3.0	123
83	Cancer Fatigue: The Way Forward. <i>Oncologist</i> , 2003, 8, 27-30.	1.9	47
84	Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. <i>Annals of Oncology</i> , 2003, 14, 511-519.	0.6	104
85	Validation Evidence for the French Canadian Adaptation of the Multidimensional Fatigue Inventory as a Measure of Cancer-related Fatigue. <i>Cancer Nursing</i> , 2003, 26, 143-154.	0.7	91
86	Dispositional pessimism predicts illness-related disruption of social and recreational activities among breast cancer patients. <i>Journal of Personality and Social Psychology</i> , 2003, 84, 813-821.	2.6	86
87	Management of Complications of Chemotherapy. , 2004, , 605-628.		0
88	Combined Modality Treatment of Aromatherapy, Footsoak, and Reflexology Relieves Fatigue in Patients with Cancer. <i>Journal of Palliative Medicine</i> , 2004, 7, 791-796.	0.6	70
89	The Evolving Role of Epoetin Alfa in Cancer Therapy. <i>Oncologist</i> , 2004, 9, 97-107.	1.9	26
90	Psychological, Behavioral, and Immune Changes After a Psychological Intervention: A Clinical Trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 3570-3580.	0.8	351
91	rHuEPO and Improved Treatment Outcomes: Potential Modes of Action. <i>Oncologist</i> , 2004, 9, 41-47.	1.9	24
92	Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatment. <i>Annals of Oncology</i> , 2004, 15, 1237-1242.	0.6	97

#	ARTICLE	IF	CITATIONS
93	Fatigue in cancer patients receiving chemotherapy: an analysis of published studies. <i>Annals of Oncology</i> , 2004, 15, 712-720.	0.6	98
94	G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma. <i>Leukemia</i> , 2004, 18, 1078-1084.	3.3	45
95	Fatigue and cancer: causes, prevalence and treatment approaches. <i>British Journal of Cancer</i> , 2004, 91, 822-828.	2.9	300
96	Course of fatigue in women receiving chemotherapy and/or radiotherapy for early stage breast cancer. <i>Journal of Pain and Symptom Management</i> , 2004, 28, 373-380.	0.6	137
97	Anemia impact and management: focus on patient needs and the use of erythropoietic agents. <i>Seminars in Oncology</i> , 2004, 31, 4-11.	0.8	11
98	Management of anemia in patients with cancer. <i>Current Oncology Reports</i> , 2004, 6, 297-304.	1.8	14
99	Fatigue, psychological distress, coping and quality of life in patients with uterine cancer. <i>Journal of Advanced Nursing</i> , 2004, 45, 205-213.	1.5	50
100	Assessing fatigue in persons with cancer. <i>Cancer</i> , 2004, 101, 1685-1695.	2.0	41
101	Current and future use of hematopoietic growth factors in cancer medicine. <i>Hematological Oncology</i> , 2004, 22, 121-134.	0.8	14
102	Clinical and Economic Impact of Epoetins in Cancer Care. <i>Pharmacoeconomics</i> , 2004, 22, 1029-1045.	1.7	23
103	Fatigue and psychological distress – exploring the relationship in women treated for breast cancer. <i>European Journal of Cancer</i> , 2004, 40, 1689-1695.	1.3	54
104	Impaired sleep and rhythms in persons with cancer. <i>Sleep Medicine Reviews</i> , 2004, 8, 199-212.	3.8	162
105	A Neuroendocrine-Based Regulatory Fatigue Model. <i>Biological Research for Nursing</i> , 2004, 6, 141-150.	1.0	43
106	Exercise as an Intervention for Cancer-Related Fatigue. <i>Physical Therapy</i> , 2004, 84, 736-743.	1.1	99
107	Altered Cortisol Response to Psychologic Stress in Breast Cancer Survivors With Persistent Fatigue. <i>Psychosomatic Medicine</i> , 2005, 67, 277-280.	1.3	195
108	A pilot examination of the impact of cancer patients' fatigue on their spousal caregivers. <i>Palliative and Supportive Care</i> , 2005, 3, 273-279.	0.6	28
109	The experience of fatigue, other symptoms and global quality of life during radiotherapy for uterine cancer. <i>International Journal of Nursing Studies</i> , 2005, 42, 377-386.	2.5	68
110	Control of common, non-pain cancer symptoms. <i>Seminars in Oncology</i> , 2005, 32, 200-210.	0.8	28

#	ARTICLE	IF	CITATIONS
111	Barriers to effective symptom management in hospice. <i>Journal of Pain and Symptom Management</i> , 2005, 29, 69-79.	0.6	39
112	Patientâ€™ provider communication and perceived control for women experiencing multiple symptoms associated with ovarian cancer. <i>Gynecologic Oncology</i> , 2005, 99, 404-411.	0.6	76
113	The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. <i>Cancer</i> , 2005, 103, 377-382.	2.0	190
114	Epidemiology of cancer-related fatigue in the Swedish twin registry. <i>Cancer</i> , 2005, 104, 2022-2031.	2.0	41
115	Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 154-160.	1.1	37
116	Comparison of proposed diagnostic criteria with FACT-F and VAS for cancer-related fatigue: proposal for use as a screening tool. <i>Supportive Care in Cancer</i> , 2005, 13, 246-254.	1.0	147
117	Occurrence of fatigue and associated factors in disease-free breast cancer patients without depression. <i>Supportive Care in Cancer</i> , 2005, 13, 628-636.	1.0	44
118	Lipid replacement/antioxidant therapy as an adjunct supplement to reduce the adverse effects of cancer therapy and restore mitochondrial function. <i>Pathology and Oncology Research</i> , 2005, 11, 139-144.	0.9	30
119	Cancer-related fatigue: An update. <i>Current Oncology Reports</i> , 2005, 7, 277-282.	1.8	34
120	Exercise manages fatigue during breast cancer treatment: A randomized controlled trial. <i>Psycho-Oncology</i> , 2005, 14, 464-477.	1.0	329
121	Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 54-62.	0.5	30
122	Recombinant human erythropoietin in oncology: current status and further developments. <i>Annals of Oncology</i> , 2005, 16, 1584-1595.	0.6	29
123	Differential Metastasis Inhibition by Clinically Relevant Levels of Heparinsâ€™ Correlation with Selectin Inhibition, Not Antithrombotic Activity. <i>Clinical Cancer Research</i> , 2005, 11, 7003-7011.	3.2	198
124	Prior Red Blood Cell Transfusions in Cancer Patients Increase the Risk of Subsequent Transfusions With or Without Recombinant Human Erythropoietin Management. <i>Oncologist</i> , 2005, 10, 63-71.	1.9	23
125	Increased Hemoglobin Levels and Improved Qualityâ€™ofâ€™Life Assessments During Epoetin Alfa Treatment in Anemic Cancer Patients: Results of a Prospective, Multicenter German Trial. <i>Oncologist</i> , 2005, 10, 225-237.	1.9	13
126	A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia. <i>Annals of Oncology</i> , 2005, 16, 1192-1198.	0.6	15
127	Social isolering -- ett omvardnadsproblem hos cancerpatienter med fatigue. <i>VÃ¥rd I Norden</i> , 2005, 25, 60-63.	0.0	3
128	Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment. <i>Annals of Oncology</i> , 2005, 16, 1545-1550.	0.6	44

#	ARTICLE	IF	CITATIONS
129	Treatment of Anemia with Erythropoietic Agents in Patients with Hematologic Malignancies. Supportive Cancer Therapy, 2005, 2, 215-224.	0.3	1
130	The role of rehabilitation medicine and palliative care in the treatment of patients with end-stage disease. Physical Medicine and Rehabilitation Clinics of North America, 2005, 16, 285-305.	0.7	14
131	The development of erythropoietic agents in oncology. Expert Opinion on Emerging Drugs, 2005, 10, 553-567.	1.0	15
132	Management of Cancer-Related Fatigue. Cancer Investigation, 2005, 23, 229-239.	0.6	166
133	Optimising the management of anaemia in patients with cancer with practice guidelines using erythropoiesis-stimulating proteins. European Journal of Oncology Nursing, 2005, 9, S3-S13.	0.9	1
134	Weekly Epoetin Alfa During Adjuvant Chemotherapy for Breast Cancer: Effect on Hemoglobin Levels and Quality of Life. Clinical Breast Cancer, 2005, 6, 132-142.	1.1	25
135	Cancer-Related Anemia. American Journal of Cancer, 2005, 4, 233-245.	0.4	10
136	The Value of Erythropoietin Therapy in Cancer Patients. American Journal of Cancer, 2005, 4, 87-103.	0.4	2
137	The Long-Term Evolution of Quality of Life for Disease-Free Breast Cancer Survivors. Journal of Psychosocial Oncology, 2006, 24, 89-123.	0.6	27
138	Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncology, The, 2006, 7, 903-909.	5.1	512
139	Darbepoetin??Alfa. Drugs, 2006, 66, 997-1012.	4.9	12
140	Targeting Anemia in Patients with Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 716-725.	0.5	6
141	Feasibility and Validity of a One-Item Fatigue Screen in a Thoracic Oncology Clinic. Journal of Thoracic Oncology, 2006, 1, 454-459.	0.5	27
142	Targeting Anemia in Patients with Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 716-725.	0.5	13
143	Course of the Fatigue Dimension "Activity Level" and the Interference of Fatigue With Daily Living Activities for Patients With Breast Cancer Receiving Adjuvant Chemotherapy. Cancer Nursing, 2006, 29, E1-E13.	0.7	18
144	Cost comparison of epoetin alpha, epoetin beta and darbepoetin alpha for cancer patients with anaemia in the clinical practice setting*. Journal of Clinical Pharmacy and Therapeutics, 2006, 31, 503-512.	0.7	10
145	A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkinâ€™s lymphoma. Annals of Hematology, 2006, 85, 301-307.	0.8	14
146	Myelotoxicity From Chemotherapy. Seminars in Oncology, 2006, 33, 74-85.	0.8	59

#	ARTICLE	IF	CITATIONS
147	A Comparison of Symptom Prevalence in Far Advanced Cancer, AIDS, Heart Disease, Chronic Obstructive Pulmonary Disease and Renal Disease. <i>Journal of Pain and Symptom Management</i> , 2006, 31, 58-69.	0.6	966
148	Supportive Intervention for Fatigue in Patients Undergoing Chemotherapy: A Randomized Controlled Trial. <i>Journal of Pain and Symptom Management</i> , 2006, 31, 148-161.	0.6	86
149	Assessing Fatigue in Persons with Cancer: Further Validation of the Wu Cancer Fatigue Scale. <i>Journal of Pain and Symptom Management</i> , 2006, 32, 255-265.	0.6	28
150	Safety, Tolerability and Symptom Outcomes Associated with L-Carnitine Supplementation in Patients with Cancer, Fatigue, and Carnitine Deficiency: A Phase I/II Study. <i>Journal of Pain and Symptom Management</i> , 2006, 32, 551-559.	0.6	84
151	Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. <i>Nutrition</i> , 2006, 22, 136-145.	1.1	157
152	Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study. <i>BMC Cancer</i> , 2006, 6, 240.	1.1	79
153	Comprehensive Symptom Management in Patients with Advanced-Stage Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2006, 7, 241-249.	1.1	70
154	Quality-of-life and health benefits of early treatment of mild anemia. <i>Cancer</i> , 2006, 107, 1909-1917.	2.0	61
155	Cancer-related anemia and recombinant human erythropoietin—an updated overview. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 152-164.	4.3	99
156	Epoetin beta in oncology: examining the current evidence. <i>Future Oncology</i> , 2006, 2, 21-38.	1.1	5
157	Efficacy and Safety of Every-2-Week Darbepoetin Alfa in Patients with Anemia of Cancer: A Controlled, Randomized, Open-Label Phase II Trial. <i>Oncologist</i> , 2007, 12, 727-737.	1.9	30
158	Pharmacologic Treatment of Cancer-Related Fatigue. <i>Oncologist</i> , 2007, 12, 43-51.	1.9	88
159	Cancer-Related Fatigue: The Scale of the Problem. <i>Oncologist</i> , 2007, 12, 4-10.	1.9	713
160	A Critical Review of Complementary Therapies for Cancer-Related Fatigue. <i>Integrative Cancer Therapies</i> , 2007, 6, 8-13.	0.8	82
161	Impact of fatigue on overall quality of life in lung and breast cancer patients selected for high-dose radiotherapy. <i>Annals of Oncology</i> , 2007, 18, 940-944.	0.6	83
162	The Effectiveness of Darbepoetin Alfa Administered Every 3 Weeks on Hematologic Outcomes and Quality of Life in Older Patients With Chemotherapy-Induced Anemia. <i>Oncologist</i> , 2007, 12, 584-593.	1.9	16
163	Clinically relevant fatigue in cancer outpatients: the Edinburgh Cancer Centre symptom study. <i>Annals of Oncology</i> , 2007, 18, 1861-1869.	0.6	56
164	Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue.. <i>Health Psychology</i> , 2007, 26, 660-667.	1.3	267

#	ARTICLE	IF	CITATIONS
165	Experiences of Fatigue and Self-management of Thai Buddhist Cancer Patients Undergoing Radiation Therapy. <i>Cancer Nursing</i> , 2007, 30, 146-155.	0.7	25
166	Chemotherapy-induced immunosuppression is restored by a fermented soybean extract: a proof of concept clinical trial. <i>Nutrition Research</i> , 2007, 27, 679-684.	1.3	14
167	Place de l'activité physique dans la prise en charge de la fatigue cancéreuse induite par les traitements oncologiques. <i>Annales De Réadaptation Et De Médecine Physique: Revue Scientifique De La Société Française De Rééducation Fonctionnelle De Réadaptation Et De Médecine Physique</i> , 2007, 50, 445-449.	0.8	4
168	Physical activity in the management of cancer-related fatigue induced by oncological treatments. <i>Annales De Réadaptation Et De Médecine Physique: Revue Scientifique De La Société Française De Rééducation Fonctionnelle De Réadaptation Et De Médecine Physique</i> , 2007, 50, 450-454.	0.8	12
169	Exercise Prevents Fatigue and Improves Quality of Life in Prostate Cancer Patients Undergoing Radiotherapy. <i>Archives of Physical Medicine and Rehabilitation</i> , 2007, 88, 1416-1422.	0.5	146
170	Risks and Benefits of Erythropoiesis-Stimulating Agents in Cancer Management. <i>Seminars in Hematology</i> , 2007, 44, 157-165.	1.8	14
171	La place des érythropoïétines en cancérologie. <i>Actualites Pharmaceutiques Hospitalieres</i> , 2007, 3, 12-17.	0.1	0
172	Cancer related fatigue: A focus on breast cancer and Hodgkin's disease survivors. <i>Acta Oncologica</i> , 2007, 46, 474-479.	0.8	74
173	Assessment and Management of Fatigue and Dyspnea in Pediatric Palliative Care. <i>Pediatric Clinics of North America</i> , 2007, 54, 735-756.	0.9	35
174	Once-weekly epoetin beta (30,000IU) in anemic patients with lung cancer receiving chemotherapy. <i>Lung Cancer</i> , 2007, 55, 89-94.	0.9	14
175	A randomized controlled trial to evaluate the effectiveness of a brief, behaviorally oriented intervention for cancer-related fatigue. <i>Cancer</i> , 2007, 110, 1385-1395.	2.0	106
176	Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia. <i>Cancer</i> , 2007, 110, 1629-1640.	2.0	30
177	Fatigue in Parkinson's disease: A review. <i>Movement Disorders</i> , 2007, 22, 297-308.	2.2	294
178	EPO in cancer anemia: Benefits and potential risks. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 62, 119-125.	2.0	15
179	Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy. <i>Cancer Gene Therapy</i> , 2007, 14, 1-11.	2.2	60
180	Web-based Health Survey Systems in Outcome Assessment and Management of Pain. <i>Pain Medicine</i> , 2007, 8, S189-S198.	0.9	13
181	Women Experience Higher Levels of Fatigue Than Men at the End of Life: A Longitudinal Home Palliative Care Study. <i>Journal of Pain and Symptom Management</i> , 2007, 33, 389-397.	0.6	37
182	The Relationship Between Cancer-Related Fatigue and Patient Satisfaction with Quality of Life in Cancer. <i>Journal of Pain and Symptom Management</i> , 2007, 34, 40-47.	0.6	113

#	ARTICLE	IF	CITATIONS
183	Letter from the Editor Interventions in Oncology: Beyond Image-Guided Therapy. <i>Seminars in Roentgenology</i> , 2007, 42, 147-148.	0.2	0
184	Anemia and quality of life including anemia-related symptoms in patients with solid tumors in clinical practice. <i>Medical Oncology</i> , 2007, 24, 95-102.	1.2	7
187	CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. <i>Annals of Hematology</i> , 2007, 86, 329-337.	0.8	96
188	Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 741-750.	1.1	52
190	Interaction of psychological factors and the effect of epoetin alfa treatment in cancer patients on hemoglobin and fatigue. <i>Supportive Care in Cancer</i> , 2007, 15, 273-278.	1.0	11
191	Editorial comment on: "The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced non-small cell lung cancer receiving palliative chemotherapy" by Vincent et al.. <i>Supportive Care in Cancer</i> , 2007, 15, 239-241.	1.0	0
192	Speed of haemoglobin response in patients with cancer: a review of the erythropoietic proteins. <i>Supportive Care in Cancer</i> , 2007, 15, 603-611.	1.0	3
193	Assessment of clinical relevant fatigue level in cancer. <i>Supportive Care in Cancer</i> , 2007, 15, 891-896.	1.0	53
194	Prospective evaluation of fatigue during a course of curative radiotherapy for localised prostate cancer. <i>Supportive Care in Cancer</i> , 2007, 15, 1169-1176.	1.0	32
195	Meeting information needs on cancer-related fatigue: an exploration of views held by Italian patients and nurses. <i>Supportive Care in Cancer</i> , 2007, 15, 1231-1241.	1.0	13
196	Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by molecular replacement therapy. <i>Clinical and Experimental Metastasis</i> , 2008, 25, 161-169.	1.7	50
197	An epidemiological study of the perception of asthenia by oncologists in cancer patients: POA study. <i>Clinical and Translational Oncology</i> , 2008, 10, 288-293.	1.2	1
198	Patients'™ perception of cancer-related fatigue: results of a survey to assess the impact on their everyday life. <i>Clinical and Translational Oncology</i> , 2008, 10, 753-757.	1.2	22
199	Clinical manifestations associated with high titer of anti-streptolysin O in Behçet's™ disease. <i>Clinical Rheumatology</i> , 2008, 27, 999-1003.	1.0	15
200	Rheumatologists'™ knowledge, attitude and current management of fatigue in patients with rheumatoid arthritis (RA). <i>Clinical Rheumatology</i> , 2008, 27, 1549-1555.	1.0	28
201	Longitudinal screening and management of fatigue, pain, and emotional distress associated with cancer therapy. <i>Supportive Care in Cancer</i> , 2008, 16, 151-159.	1.0	26
202	The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study: a global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines. <i>Supportive Care in Cancer</i> , 2008, 16, 193-200.	1.0	15
203	Conducting routine fatigue assessments for use in clinical oncology practice: patient and provider perspectives. <i>Supportive Care in Cancer</i> , 2008, 16, 379-386.	1.0	16

#	ARTICLE	IF	CITATIONS
204	Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S.. Supportive Care in Cancer, 2008, 16, 791-801.	1.0	303
205	Association between fatigue and other cancer-related symptoms in patients with advanced cancer. Supportive Care in Cancer, 2008, 16, 1125-1130.	1.0	59
206	Development and evaluation of a cancer-related fatigue patient education program: protocol of a randomized controlled trial. BMC Nursing, 2008, 7, 12.	0.9	6
207	Development of a fatigue and functional impact scale in anemic cancer patients receiving chemotherapy. Cancer, 2008, 113, 1480-1488.	2.0	16
208	Patient-Physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer. Cancer, 2008, 113, 2205-2214.	2.0	102
209	Determinants of overall quality of life in preterminal cancer patients. International Journal of Cancer, 2008, 123, 232-235.	2.3	37
210	Presence, communication and treatment of fatigue and pain complaints in incurable cancer patients. Patient Education and Counseling, 2008, 72, 102-108.	1.0	13
211	Clinical factors associated with fatigue over time in paediatric oncology patients receiving chemotherapy. British Journal of Cancer, 2008, 99, 23-29.	2.9	46
212	Health State Utility Scores for Cancer-Related Anemia through Societal and Patient Valuations. Value in Health, 2008, 11, 1178-1185.	0.1	30
213	The psychosocial concerns and needs of women recently diagnosed with breast cancer: a qualitative study of patient, nurse and volunteer perspectives. Health Expectations, 2008, 11, 331-342.	1.1	67
214	Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer, 2008, 8, 266.	1.1	355
215	Fatigue in osteoarthritis: a qualitative study. BMC Musculoskeletal Disorders, 2008, 9, 63.	0.8	119
216	Use of a Single-Item Screening Tool to Detect Clinically Significant Fatigue, Pain, Distress, and Anorexia in Ambulatory Cancer Practice. Journal of Pain and Symptom Management, 2008, 35, 20-30.	0.6	158
217	An Interdisciplinary Care Approach for Integration of Palliative Care in Lung Cancer. Clinical Lung Cancer, 2008, 9, 352-360.	1.1	36
218	Fatigue in palliative care patients – an EAPC approach. Palliative Medicine, 2008, 22, 13-32.	1.3	250
220	Anemia in Patients With Cancer or Undergoing Cancer Therapy: Impact and Current Treatment Practice. Transfusion Alternatives in Transfusion Medicine, 2005, 6, 14-25.	0.2	2
221	Breast Cancer and Fatigue. Sleep Medicine Clinics, 2008, 3, 61-71.	1.2	81
222	Analisi dei consumi e dei costi degli agenti stimolanti l'ematopoiesi nel trattamento dell'anemia nei pazienti con insufficienza renale cronica. Pharmacoeconomics Italian Research Articles, 2008, 10, 161-169.	0.2	1

#	ARTICLE	IF	CITATIONS
223	Intestinal Transporters in Drug Absorption. , 2008, , 175-261.		5
224	Pharmacotherapy of anemia in cancer patients. Expert Review of Clinical Pharmacology, 2008, 1, 307-317.	1.3	2
225	Cancer-Related Fatigue: Role of Oncology Nurses in Translating National Comprehensive Cancer Network Assessment Guidelines Into Practice. Clinical Journal of Oncology Nursing, 2008, 12, 37-47.	0.3	77
226	A systematic comparison of fatigue levels in systemic sclerosis with general population, cancer and rheumatic disease samples. Rheumatology, 2008, 47, 1559-1563.	0.9	49
227	Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia. Expert Review of Anticancer Therapy, 2008, 8, 875-885.	1.1	3
230	End of life care in chronic obstructive pulmonary disease: in search of a good death. International Journal of COPD, 2008, Volume 3, 11-29.	0.9	60
231	The Impact of a Long-Acting Erythropoiesis Stimulating Protein on Patient Throughput in a Hospital-Based Ambulatory Oncology Clinic. Hospital Pharmacy, 2008, 43, 388-395.	0.4	3
232	Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data. The Cochrane Library, 2009, , CD007303.	1.5	98
233	Patient-Related Barriers to Fatigue Communication in Cancer Patients Receiving Active Treatment. Oncologist, 2009, 14, 936-943.	1.9	36
234	The Measurement of Fatigue in Chronic Illness: A Systematic Review of Unidimensional and Multidimensional Fatigue Measures. Journal of Pain and Symptom Management, 2009, 37, 107-128.	0.6	333
235	A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Impact of Dexamphetamine on Fatigue in Patients with Advanced Cancer. Journal of Pain and Symptom Management, 2009, 37, 613-621.	0.6	61
236	L-Carnitine Supplementation in Patients with Advanced Cancer and Carnitine Deficiency: A Double-Blind, Placebo-Controlled Study. Journal of Pain and Symptom Management, 2009, 37, 622-631.	0.6	63
237	The Utility of Screening in the Design of Trials for Symptom Management in Cancer. Journal of Pain and Symptom Management, 2009, 38, 606-614.	0.6	8
238	Efficacy of Dexmethylphenidate for the Treatment of Fatigue After Cancer Chemotherapy: A Randomized Clinical Trial. Journal of Pain and Symptom Management, 2009, 38, 650-662.	0.6	172
239	Impact of a walking intervention on cardiorespiratory fitness, self-reported physical function, and pain in patients undergoing treatment for solid tumors. Cancer, 2009, 115, 4874-4884.	2.0	84
240	Evaluation of a mobile phone-based, advanced symptom management system (ASyMSA©) in the management of chemotherapy-related toxicity. Supportive Care in Cancer, 2009, 17, 437-444.	1.0	246
241	Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study). Supportive Care in Cancer, 2009, 17, 1071-1080.	1.0	47
242	Transferrin Receptor Targeted Lipopolyplexes for Delivery of Antisense Oligonucleotide G3139 in a Murine K562 Xenograft Model. Pharmaceutical Research, 2009, 26, 1516-1524.	1.7	38

#	ARTICLE	IF	CITATIONS
243	Arousal frequency is associated with increased fatigue in obstructive sleep apnea. <i>Sleep and Breathing</i> , 2009, 13, 331-339.	0.9	31
245	Response analysis for multiple symptoms revealed differences between arms of a symptom management trial. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 716-724.	2.4	27
246	Modafinil for the treatment of fatigue in lung cancer: a pilot study. <i>Palliative Medicine</i> , 2009, 23, 325-331.	1.3	46
247	Analisi di minimizzazione dei costi degli agenti stimolanti l'ematopoiesi nel trattamento dell'anemia indotta da chemioterapia. <i>Pharmacoeconomics Italian Research Articles</i> , 2009, 11, 15-23.	0.2	1
248	Valutazione economica di epoetina alfa nel trattamento dell'anemia indotta da chemioterapia: una revisione sistematica della letteratura. <i>Giornale Italiano Di Health Technology Assessment</i> , 2009, 2, 37-45.	0.1	0
249	Inducible expression of beta defensins by human respiratory epithelial cells exposed to <i>Aspergillus fumigatus</i> organisms. <i>BMC Microbiology</i> , 2009, 9, 33.	1.3	67
250	Differential Symptom Reporting by Mode of Administration of the Assessment. <i>Medical Care</i> , 2009, 47, 866-874.	1.1	25
251	Pre and peri-operative erythropoietin for reducing allogeneic blood transfusions in colorectal cancer surgery. <i>The Cochrane Library</i> , 2009, , CD007148.	1.5	30
257	Kinesitherapy alleviates fatigue in terminal hospice cancer patients: an experimental, controlled study. <i>Supportive Care in Cancer</i> , 2010, 18, 743-749.	1.0	27
258	Theory-Based Evaluation of an Online Cancer Fatigue Class. <i>Journal of Cancer Education</i> , 2010, 25, 422-430.	0.6	4
259	Lipid replacement therapy: a nutraceutical approach for reducing cancer-associated fatigue and the adverse effects of cancer therapy while restoring mitochondrial function. <i>Cancer and Metastasis Reviews</i> , 2010, 29, 543-552.	2.7	40
260	How so tired: biological and genetic mechanisms of cancer-related fatigue. <i>Quality of Life Research</i> , 2010, 19, 1419-1427.	1.5	163
261	Reducing Patient Barriers to Pain and Fatigue Management. <i>Journal of Pain and Symptom Management</i> , 2010, 39, 486-501.	0.6	63
262	Age-Associated Differences in Fatigue Among Patients with Cancer. <i>Journal of Pain and Symptom Management</i> , 2010, 40, 217-223.	0.6	31
263	Fatigue in Children with Cancer at the End of Life. <i>Journal of Pain and Symptom Management</i> , 2010, 40, 483-494.	0.6	48
264	Minimal important differences and response shift in health-related quality of life; a longitudinal study in patients with multiple myeloma. <i>Health and Quality of Life Outcomes</i> , 2010, 8, 79.	1.0	56
265	Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer. <i>Cancer</i> , 2010, 116, 766-774.	2.0	111
266	Effect of methylphenidate on fatigue in women with recurrent gynecologic cancer. <i>Psycho-Oncology</i> , 2010, 19, 955-958.	1.0	20

#	ARTICLE	IF	CITATIONS
267	Quality of Life and Fatigue in Hodgkin's Lymphoma Patients. Tumori, 2010, 96, 594-600.	0.6	15
268	CANCER-RELATED FATIGUE. Acta Clinica Belgica, 2010, 65, 378-385.	0.5	19
269	Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Long-Acting Methylphenidate for Cancer-Related Fatigue: North Central Cancer Treatment Group NCCTG-N05C7 Trial. Journal of Clinical Oncology, 2010, 28, 3673-3679.	0.8	160
270	Cancer-Related Fatigue: State of the Science. PM and R, 2010, 2, 364-383.	0.9	139
271	Analisi dei consumi e dei costi degli agenti stimolanti l'ematropoiesi nel trattamento dell'anemia nei pazienti con insufficienza renale cronica: l'esperienza della ASL della provincia di Alessandria. Pharmacoconomics Italian Research Articles, 2010, 12, 167-174.	0.2	1
272	Analisi dei costi degli agenti stimolanti l'ematropoiesi nel trattamento dell'anemia indotta da chemioterapia: l'esperienza della ASL della provincia di Alessandria. Pharmacoconomics Italian Research Articles, 2010, 12, 175-182.	0.2	1
273	Effectiveness of a Clinical Intervention to Eliminate Barriers to Pain and Fatigue Management in Oncology. Journal of Palliative Medicine, 2011, 14, 197-205.	0.6	40
274	Cancer-related fatigue: a review. Revista Da Associação Médica Brasileira (English Edition), 2011, 57, 206-214.	0.1	1
275	Fadiga relacionada ao câncer: uma revisão. Revista Da Associação Médica Brasileira, 2011, 57, 211-219.	0.3	88
277	Factors correlated with fatigue in breast cancer patients before, during and after adjuvant chemotherapy: The FATSEIN study. Contemporary Clinical Trials, 2011, 32, 244-249.	0.8	13
278	Part A. , 2011, , 129-144.		0
279	Cancer-related fatigue. , 2011, , 136-149.		0
280	Cancer Rehabilitation: Experience, Symptoms, and Needs. Journal of Korean Medical Science, 2011, 26, 619.	1.1	9
281	Treatment of Chronic Pain by Long-Acting Opioids and the Effects on Sleep. Pain Practice, 2011, 11, 282-289.	0.9	23
282	Parsing Depression From Fatigue in Patients with Cancer Using the Fatigue Symptom Inventory. Journal of Pain and Symptom Management, 2011, 42, 52-59.	0.6	15
283	Cancer-related fatigue: clinical practice versus practice guidelines. Supportive Care in Cancer, 2011, 19, 531-538.	1.0	30
284	Psychometric properties of the Perform Questionnaire: a brief scale for assessing patient perceptions of fatigue in cancer. Supportive Care in Cancer, 2011, 19, 657-666.	1.0	23
286	Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in haemoglobin level. Clinical and Translational Oncology, 2011, 13, 341-347.	1.2	11

#	ARTICLE	IF	CITATIONS
287	An examination of cancer-related fatigue through proposed diagnostic criteria in a sample of cancer patients in Taiwan. <i>BMC Cancer</i> , 2011, 11, 387.	1.1	22
288	Cross-cultural development of an item list for computer-adaptive testing of fatigue in oncological patients. <i>Health and Quality of Life Outcomes</i> , 2011, 9, 19.	1.0	24
289	Natural and synthetic cathelicidin peptides with anti-microbial and anti-biofilm activity against <i>Staphylococcus aureus</i> . <i>BMC Microbiology</i> , 2011, 11, 114.	1.3	188
290	Symptom management in gynecologic malignancies. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1079-1091.	1.1	17
291	Cancer-related fatigue: a practical review. <i>Annals of Oncology</i> , 2011, 22, 1273-1279.	0.6	171
292	Factors Associated with Response to Methylphenidate in Advanced Cancer Patients. <i>Oncologist</i> , 2011, 16, 246-253.	1.9	28
293	Doxorubicin and daunorubicin induce processing and release of interleukin-1 $\beta$ through activation of the NLRP3 inflammasome. <i>Cancer Biology and Therapy</i> , 2011, 11, 1008-1016.	1.5	165
294	Age- and sex-standardised prevalence rates of fatigue in a large hospital-based sample of cancer patients. <i>British Journal of Cancer</i> , 2011, 105, 445-451.	2.9	77
295	Palliative Care and Quality of Life. , 2012, , 597-630.e6.		0
296	Time Course and Predictors for Cancer-Related Fatigue in a Series of Oropharyngeal Cancer Patients Treated with Chemoradiation Therapy. <i>Oncologist</i> , 2012, 17, 569-576.	1.9	22
297	Agreement between self-report and medical records on signs and symptoms of respiratory illness. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2012, 21, 145-152.	2.5	33
298	Senior Adult Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 162-209.	2.3	105
299	The Correlation of Traditional Chinese Medicine Deficiency Syndromes, Cancer Related Fatigue, and Quality of Life in Breast Cancer Patients. <i>Journal of Traditional and Complementary Medicine</i> , 2012, 2, 204-210.	1.5	21
300	The investigation and treatment of secondary anaemia. <i>Blood Reviews</i> , 2012, 26, 65-71.	2.8	28
301	Disorders of Phagocytic Cells. , 2012, , 193-231.		3
302	Shwachmanâ€™Diamond syndrome. <i>Musculoskeletal Surgery</i> , 2012, 96, 81-88.	0.7	13
303	The anemia impact measure (AIM): development and content validation of a patient-reported outcome measure of anemia symptoms and symptom impacts in cancer patients receiving chemotherapy. <i>Quality of Life Research</i> , 2012, 21, 1255-1266.	1.5	13
304	Biomarkers of Therapeutic Response to BCL2 Antagonists in Cancer. <i>Molecular Diagnosis and Therapy</i> , 2012, 16, 347-356.	1.6	13

#	ARTICLE	IF	CITATIONS
305	Fatigue in patients undergoing chemotherapy, their self-care and the role of health professionals: A qualitative study. <i>European Journal of Oncology Nursing</i> , 2012, 16, 165-171.	0.9	42
306	Quality of life and barriers to symptom management in colon cancer. <i>European Journal of Oncology Nursing</i> , 2012, 16, 276-280.	0.9	37
307	Impact of partial versus whole breast radiation therapy on fatigue, perceived stress, quality of life and natural killer cell activity in women with breast cancer. <i>BMC Cancer</i> , 2012, 12, 251.	1.1	34
308	Apoptosis and Male Infertility. , 2012, , 329-336.		3
309	Physical symptom profile for adult cancer inpatients at a Lebanese cancer unit. <i>European Journal of Internal Medicine</i> , 2012, 23, e185-e189.	1.0	14
310	Cancer-Related Fatigue. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2012, 109, 161-71; quiz 172.	0.6	208
311	A Randomized, Double-Blind, Placebo-Controlled Study of Oral Coenzyme Q10 to Relieve Self-Reported Treatment-Related Fatigue in Newly Diagnosed Patients with Breast Cancer. <i>The Journal of Supportive Oncology</i> , 2012, 11, 31-42.	2.3	50
312	Mindfulness-based cognitive therapy reduces chronic cancer-related fatigue: a treatment study. <i>Psycho-Oncology</i> , 2012, 21, 264-272.	1.0	134
313	Effects of Methylphenidate on Fatigue and Depression: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Pain and Symptom Management</i> , 2012, 43, 68-77.	0.6	144
314	Psychometric evaluation of the EORTC computerized adaptive test (CAT) fatigue item pool. <i>Quality of Life Research</i> , 2013, 22, 2443-2454.	1.5	22
315	Deriving clinically meaningful cut-scores for fatigue in a cohort of breast cancer survivors: a Health, Eating, Activity, and Lifestyle (HEAL) Study. <i>Quality of Life Research</i> , 2013, 22, 2279-2292.	1.5	22
316	Using aggregated single patient (N-of-1) trials to determine the effectiveness of psychostimulants to reduce fatigue in advanced cancer patients: a rationale and protocol. <i>BMC Palliative Care</i> , 2013, 12, 17.	0.8	21
317	The prevalence and severity of fatigue in men with prostate cancer: a systematic review of the literature. <i>Supportive Care in Cancer</i> , 2013, 21, 1761-1771.	1.0	69
318	Prevalence, predictors, and prognostic impact of fatigue among Brazilian outpatients with advanced cancers. <i>Supportive Care in Cancer</i> , 2013, 21, 1053-1060.	1.0	25
319	A narrative literature review of older people's cancer pain experience. <i>Journal of Clinical Nursing</i> , 2013, 22, 2100-2113.	1.4	9
320	Adapted physical activity and diet (APAD) during adjuvant breast cancer therapy: Design and implementation of a prospective randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2013, 36, 531-543.	0.8	13
321	Breast Cancer Survivorship Issues. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 805-827.	0.9	54
322	Developing outcome measures for pediatric mitochondrial disorders: Which complaints and limitations are most burdensome to patients and their parents?. <i>Mitochondrion</i> , 2013, 13, 15-24.	1.6	34

#	ARTICLE	IF	CITATIONS
323	Measurement of fatigue in cancer, stroke, and HIV using the Functional Assessment of Chronic Illness Therapy " Fatigue (FACIT-F) scale. <i>Journal of Psychosomatic Research</i> , 2013, 74, 64-68.	1.2	91
324	Appropriateness of the treatment of fatigued patients with stage IV cancer. <i>Supportive Care in Cancer</i> , 2013, 21, 229-233.	1.0	20
325	Molecular mechanisms underlying skeletal muscle weakness in human cancer: reduced myosin-actin cross-bridge formation and kinetics. <i>Journal of Applied Physiology</i> , 2013, 114, 858-868.	1.2	44
326	Capturing Acute Toxicity Data During Lung Radiotherapy by Using a Patient-Reported Assessment Tool. <i>Clinical Lung Cancer</i> , 2013, 14, 108-112.	1.1	6
327	Differences in morning and evening fatigue in oncology patients and their family caregivers. <i>European Journal of Oncology Nursing</i> , 2013, 17, 841-848.	0.9	26
328	Epidemiology and Outcomes of Regimen-Related Toxicities. , 2013, , 3-17.		0
329	Assessment of Daily and Weekly Fatigue Among African American Cancer Survivors. <i>Journal of Psychosocial Oncology</i> , 2013, 31, 413-429.	0.6	9
330	Impact of a Home-Based Walking Intervention on Outcomes of Sleep Quality, Emotional Distress, and Fatigue in Patients Undergoing Treatment for Solid Tumors. <i>Oncologist</i> , 2013, 18, 476-484.	1.9	55
331	Impairment-driven cancer rehabilitation: An essential component of quality care and survivorship. <i>Ca-A Cancer Journal for Clinicians</i> , 2013, 63, 295-317.	157.7	316
332	Determining Chemotherapy Tolerance in Older Patients With Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1494-1502.	2.3	36
333	The course of fatigue in patients with gynecologic and breast cancer. <i>Journal of Gynecologic Oncology</i> , 2013, 24, 280.	1.0	12
334	Effect of Prophylactic Low Level Laser Therapy on Oral Mucositis: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e107418.	1.1	134
335	Discerning Primary and Secondary Factors Responsible for Clinical Fatigue in Multisystem Diseases. <i>Biology</i> , 2014, 3, 606-622.	1.3	8
336	Erythropoiesis-stimulating agents and quality of life: personal journeys of a cancer survivor, oncologist, and two cancer health services researchers. <i>British Journal of Cancer</i> , 2014, 111, 421-423.	2.9	2
337	Pedometer-facilitated walking intervention shows promising effectiveness for reducing cancer fatigue: a pilot randomized trial. <i>Clinical Rehabilitation</i> , 2014, 28, 1198-1209.	1.0	31
338	The Effect of Intravenous Vitamin C on Cancer- and Chemotherapy-Related Fatigue and Quality of Life. <i>Frontiers in Oncology</i> , 2014, 4, 283.	1.3	75
339	MS-20, A Chemotherapeutical Adjuvant, Reduces Chemo-Associated Fatigue and Appetite Loss in Cancer Patients. <i>Nutrition and Cancer</i> , 2014, 66, 1211-1219.	0.9	5
340	A Randomized, Double-blind, 2-Period, Placebo-Controlled Crossover Trial of a Sustained-Release Methylphenidate in the Treatment of Fatigue in Cancer Patients. <i>Cancer Journal (Sudbury, Mass )</i> , 2014, 20, 8-14.	1.0	76

#	ARTICLE	IF	CITATIONS
341	The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study. <i>Supportive Care in Cancer</i> , 2014, 22, 181-187.	1.0	175
342	Cancer-related fatigue—mechanisms, risk factors, and treatments. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 597-609.	12.5	998
343	A pleomorphic carcinoma of the lung producing multiple cytokines and forming a rapidly progressive mass-like opacity. <i>BMC Cancer</i> , 2014, 14, 588.	1.1	7
344	Prognostic significance of blood transfusion and anaemia on survival in stage IIIA/B/C and IVA oesophageal cancers treated with chemoradiotherapy. <i>Journal of Radiation Oncology</i> , 2014, 3, 167-177.	0.7	2
345	Fatigue during chemoradiotherapy for nasopharyngeal cancer and its relationship to radiation dose distribution in the brain. <i>Radiotherapy and Oncology</i> , 2014, 110, 416-421.	0.3	30
346	Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. <i>Annals of Hematology</i> , 2014, 93, 1263-1277.	0.8	48
347	Management of fatigue in patients with cancer – A practical overview. <i>Cancer Treatment Reviews</i> , 2014, 40, 791-799.	3.4	87
348	Persistent Posttreatment Fatigue in Thyroid Cancer Survivors. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 475-494.	1.2	24
349	Randomized trial of exercise and an online recovery tool to improve rehabilitation outcomes of cancer survivors. <i>Physician and Sportsmedicine</i> , 2015, 43, 143-149.	1.0	10
351	Epoetin beta for the treatment of chemotherapy-induced anemia: an update. <i>OncoTargets and Therapy</i> , 2015, 8, 583.	1.0	5
352	Measuring the quality of patient-centered care: why patient-reported measures are critical to reliable assessment. <i>Patient Preference and Adherence</i> , 2015, 9, 831.	0.8	108
353	Role of P-Glycoprotein for Resistance of Tumors to Anticancer Drugs: From Bench to Bedside. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015, , 1-26.	0.1	9
354	Teenage and Young Adult Cancer-Related Fatigue Is Prevalent, Distressing, and Neglected: It Is Time to Intervene. A Systematic Literature Review and Narrative Synthesis. <i>Journal of Adolescent and Young Adult Oncology</i> , 2015, 4, 3-17.	0.7	78
355	Understanding the molecular aspects of oriental obesity pattern differentiation using DNA microarray. <i>Journal of Translational Medicine</i> , 2015, 13, 331.	1.8	1
358	Can the Cancer-related Fatigue Case-definition Criteria Be Applied to Chronic Medical Illness? A Comparison between Breast Cancer and Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2015, 42, 1156-1162.	1.0	5
359	Bringing <scp>PROMIS</scp> to practice: Brief and precise symptom screening in ambulatory cancer care. <i>Cancer</i> , 2015, 121, 927-934.	2.0	179
360	The Effect of Methylphenidate on Fatigue in Advanced Cancer: An Aggregated N-of-1 Trial. <i>Journal of Pain and Symptom Management</i> , 2015, 50, 289-296.	0.6	40
361	Chemotherapy interruptions in relation to symptom severity in advanced breast cancer. <i>Supportive Care in Cancer</i> , 2015, 23, 3183-3191.	1.0	35

#	ARTICLE	IF	CITATIONS
362	The CXCR1/2 Pathway: Involvement in Diabetes Pathophysiology and Potential Target for T1D Interventions. <i>Current Diabetes Reports</i> , 2015, 15, 68.	1.7	29
363	Advances in Supportive Care for Late Effects of Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3314-3321.	0.8	92
364	Development of the Hirai Cancer Fatigue Scale: Testing its reliability and validity. <i>European Journal of Oncology Nursing</i> , 2015, 19, 427-432.	0.9	5
365	Effect of Processed Honey and Royal Jelly on Cancer-Related Fatigue: A Double-Blind Randomized Clinical Trial. <i>Electronic Physician</i> , 2016, 8, 2475-2482.	0.2	26
366	Physiology of Hemostasis. , 2016, , 3-16.		1
367	Patient and health care provider perceptions of cancer-related fatigue and pain. <i>Supportive Care in Cancer</i> , 2016, 24, 4357-4363.	1.0	50
368	Fatigue among patients with brain tumors. <i>CNS Oncology</i> , 2016, 5, 91-100.	1.2	49
369	Feasibility and diagnostic accuracy of the Patient-Reported Outcomes Measurement Information System (PROMIS) item banks for routine surveillance of sleep and fatigue problems in ambulatory cancer care. <i>Cancer</i> , 2016, 122, 2906-2917.	2.0	31
372	Fatigue in adolescent and adult survivors of non-CNS childhood cancer: a report from project REACH. <i>Supportive Care in Cancer</i> , 2016, 24, 3951-3959.	1.0	19
373	Systematic Review: Insight into Antimalarial Peptide. <i>International Journal of Peptide Research and Therapeutics</i> , 2016, 22, 325-340.	0.9	9
374	An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder. <i>Journal of Affective Disorders</i> , 2016, 194, 115-119.	2.0	35
375	Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 319-325.	12.5	179
376	Results from the LIDO anemia survey: adherence to EORTC guidelines in cancer patients in France. <i>Supportive Care in Cancer</i> , 2016, 24, 3347-3351.	1.0	0
377	The use of corticosteroids in reducing cancer-related fatigue: assessing the evidence for clinical practice. <i>International Journal of Palliative Nursing</i> , 2016, 22, 5-9.	0.2	11
378	Red Blood Cell Transfusion Strategies in Adult and Pediatric Patients with Malignancy. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 529-540.	0.9	15
379	Relationship between fatigue, sleep quality and inflammatory cytokines during external beam radiation therapy for prostate cancer: A prospective study. <i>Radiotherapy and Oncology</i> , 2016, 118, 105-111.	0.3	36
380	Cancer-related fatigue and associated disability in post-treatment cancer survivors. <i>Journal of Cancer Survivorship</i> , 2016, 10, 51-61.	1.5	227
381	Clinical Case Report: Yoga for Fatigue in Five Young Adult Survivors of Childhood Cancer. <i>Journal of Adolescent and Young Adult Oncology</i> , 2017, 6, 96-101.	0.7	16

#	ARTICLE	IF	CITATIONS
382	A systematic review of the association between fatigue and genetic polymorphisms. <i>Brain, Behavior, and Immunity</i> , 2017, 62, 230-244.	2.0	50
383	Patient-reported symptoms of radiation dermatitis during breast cancer radiotherapy: a pilot study. <i>Quality of Life Research</i> , 2017, 26, 1713-1719.	1.5	35
384	Advancing the efficiency and efficacy of patient reported outcomes with multivariate computer adaptive testing. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017, 24, 897-902.	2.2	17
385	<i>Principles of Cancer Rehabilitation.</i> , 2017, , 279-296.		2
386	Psychometric Properties of the Fatigue Questionnaire EORTC QLQ-FA12 in a Sample of Female Cancer Patients. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 922-928.	0.6	20
387	Exploring Genetic Attributions Underlying Radiotherapy-Induced Fatigue in Prostate Cancer Patients. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 326-339.	0.6	7
388	Longitudinal perceptions of the side effects of chemotherapy in patients with gynecological cancer. <i>Supportive Care in Cancer</i> , 2017, 25, 3457-3464.	1.0	38
389	Quantitative real time PCR analysis of apoptotic gene expression in chronic lymphocytic leukemia patients and their relationships with chemosensitivity. <i>Applied Cancer Research</i> , 2017, 37, .	1.0	3
390	HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. <i>Leukemia</i> , 2017, 31, 301-309.	3.3	61
391	<i>Schmerztherapie und Symptomkontrolle in der Palliativmedizin.</i> , 2017, , 371-377.		0
392	Symptoms Relevant to Surveillance for Ovarian Cancer. <i>Diagnostics</i> , 2017, 7, 18.	1.3	5
394	Developing an Integrative Treatment Program for Cancer-Related Fatigue Using Stakeholder Engagement – A Qualitative Study. <i>Integrative Cancer Therapies</i> , 2018, 17, 762-773.	0.8	8
395	The role of suboptimal mitochondrial function in vulnerability to post-traumatic stress disorder. <i>Journal of Inherited Metabolic Disease</i> , 2018, 41, 585-596.	1.7	27
396	Late treatment effects following bone marrow transplant: Efficacy of implementing international guidelines. <i>European Journal of Cancer Care</i> , 2018, 27, e12623.	0.7	6
397	<i>Palliative Care and Quality of Life.</i> , 2018, , 528-559.e7.		1
398	Restriction of drug transport by the tumor environment. <i>Histochemistry and Cell Biology</i> , 2018, 150, 631-648.	0.8	16
399	Fatigue and the wear-off effect in adult patients with common variable immunodeficiency. <i>Clinical and Experimental Immunology</i> , 2018, 194, 327-338.	1.1	14
400	The challenge of drug resistance in cancer treatment: a current overview. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 309-318.	1.7	354

#	ARTICLE	IF	CITATIONS
401	Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 256-264.	1.2	19
402	Survivorship issues as determinants of quality of life after breast cancer treatment: Report from a limited resource setting. <i>Breast</i> , 2018, 41, 120-126.	0.9	24
403	Signal Transduction Pathways Associated with KSHV-Related Tumors. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1045, 321-355.	0.8	10
404	Complications of Radiotherapy and Radiosurgery in the Brain and Spine. <i>Neurographics</i> , 2018, 8, 167-187.	0.2	4
405	Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO). <i>Supportive Care in Cancer</i> , 2019, 27, 1041-1047.	1.0	35
406	Short- and long-term impact of adapted physical activity and diet counseling during adjuvant breast cancer therapy: the "APAD" randomized controlled trial. <i>BMC Cancer</i> , 2019, 19, 737.	1.1	73
408	PREVALENCE OF FATIGUE AND IMPACT ON QUALITY OF LIFE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: the VITAL study. <i>BMC Urology</i> , 2019, 19, 92.	0.6	20
409	The effectiveness of moxibustion for cancer-related fatigue: An updated systematic review and meta-analysis. <i>European Journal of Integrative Medicine</i> , 2019, 30, 100960.	0.8	4
410	Assessing Treatment-Related Toxicity Using Administrative Data, Patient-Reported Outcomes, or Physician-Graded Toxicity: Where Is the Truth?. <i>Seminars in Radiation Oncology</i> , 2019, 29, 333-337.	1.0	6
411	Karnofsky Performance Status as A Predictive Factor for Cancer-Related Fatigue Treatment with Astragalus Polysaccharides (PG2) Injection—A Double Blind, Multi-Center, Randomized Phase IV Study. <i>Cancers</i> , 2019, 11, 128.	1.7	27
412	Cancer related fatigue in prostate cancer. <i>Translational Andrology and Urology</i> , 2019, 8, S106-S108.	0.6	3
413	Fatigue Associated with Radiation Treatment for Breast Cancer. , 2019, , 23-38.		1
414	Prevalence of Fatigue in Head and Neck Cancer Survivors. <i>Annals of Otolaryngology and Rhinology</i> , 2019, 128, 413-419.	0.6	30
415	The efficacy and safety of Kyung-Ok-Ko on cancer-related fatigue in lung cancer patients. <i>Medicine (United States)</i> , 2019, 98, e17717.	0.4	1
416	Incorporation of Astragalus polysaccharides injection during concurrent chemoradiotherapy in advanced pharyngeal or laryngeal squamous cell carcinoma: preliminary experience of a phase II double-blind, randomized trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 33-41.	1.2	22
417	Cancer Rehabilitation. <i>Medical Clinics of North America</i> , 2020, 104, 239-250.	1.1	18
418	Longitudinal Trend of Health-Related Quality of Life During Concurrent Chemoradiotherapy and Survival in Patients With Stage II-IVb Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 579292.	1.3	1
419	How Confident Are We at Assessing and Managing Fatigue in Palliative Care Patients? A Multicenter Survey Exploring the Current Attitudes of Palliative Care Professionals. <i>Palliative Medicine Reports</i> , 2020, 1, 58-65.	0.4	3

#	ARTICLE	IF	CITATIONS
420	Brief Hospital Supervision of Exercise and Diet During Adjuvant Breast Cancer Therapy Is Not Enough to Relieve Fatigue: A Multicenter Randomized Controlled Trial. <i>Nutrients</i> , 2020, 12, 3081.	1.7	15
421	Quality of Life, Toxicity and Unmet Needs in Nasopharyngeal Cancer Survivors. <i>Frontiers in Oncology</i> , 2020, 10, 930.	1.3	31
422	Cancer-Related Anemia Is a Risk Factor for Medium-Term Postoperative Cognitive Dysfunction in Laparoscopic Surgery Patients: An Observational Prospective Study. <i>Neural Plasticity</i> , 2020, 2020, 1-7.	1.0	6
423	Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1685-1692.	0.8	86
424	Cancer-related fatigue among long-term survivors of breast, cervical, and colorectal cancer: a French registry-based controlled study. <i>Supportive Care in Cancer</i> , 2020, 28, 5839-5849.	1.0	18
425	A nationwide survey of fatigue in cancer patients in Taiwan: an unmet need. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 693-700.	0.6	10
426	Survey on symptoms in patients receiving chemotherapy in an Italian department of oncology: a comparison between period prevalences. <i>Supportive Care in Cancer</i> , 2021, 29, 255-261.	1.0	4
427	Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 629-636.	1.4	22
428	The Level of Distress From Fatigue Reported in the Final Two Months of Life by a Palliative Care Population: An Australian National Prospective, Consecutive Case Series. <i>Journal of Pain and Symptom Management</i> , 2021, 61, 1109-1117.	0.6	4
429	Interventions for multidimensional aspects of breast cancer-related fatigue: a meta-analytic review. <i>Supportive Care in Cancer</i> , 2021, 29, 1753-1764.	1.0	15
430	Prediction of evening fatigue severity in outpatients receiving chemotherapy: less may be more. <i>Fatigue: Biomedicine, Health and Behavior</i> , 2021, 9, 14-32.	1.2	8
431	Computational study on novel natural inhibitors targeting BCL2. <i>Medical Oncology</i> , 2021, 38, 94.	1.2	2
432	Psycho-Oncology: A Bibliometric Review of the 100 Most-Cited Articles. <i>Healthcare (Switzerland)</i> , 2021, 9, 1008.	1.0	4
433	Fatigue as the Chief Complaint. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2021, 118, 566-576.	0.6	11
434	Association of Fatigue and Outcomes in Advanced Cancer: An Analysis of Four SWOG Treatment Trials. <i>JCO Oncology Practice</i> , 2021, 17, e1246-e1257.	1.4	8
435	Erythropoietic therapy in the practice of oncology. , 2003, , 163-184.		2
437	Medical and Psychosocial Issues in Prostate Cancer Survivors. , 2007, , 145-156.		3
438	Palliative Care in the Emergency Center. , 2016, , 273-285.		2

#	ARTICLE	IF	CITATIONS
439	Cost-effectiveness of treating cancer anaemia. , 2008, , 813-849.		1
440	Studies of erythropoiesis and the discovery and cloning of recombinant human erythropoietin. , 2009, , 77-85.		4
441	Disorders of Blood Cell Production in Clinical Oncology. , 2008, , 677-692.		2
442	Cancer-related fatigue: a review. Revista Da Associação Médica Brasileira, 2011, 57, 206-214.	0.3	12
443	Fatigue in cancer patients. Current Opinion in Oncology, 1999, 11, 244.	1.1	35
444	Feasibility and Validity of a One-Item Fatigue Screen in a Thoracic Oncology Clinic. Journal of Thoracic Oncology, 2006, 1, 454-459.	0.5	25
445	Fatigue in cancer. BMJ: British Medical Journal, 2001, 322, 1560-1560.	2.4	64
446	PlenadrEMA: effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments: a study protocol for an open-label switch pilot study. BMJ Open, 2018, 8, e019487.	0.8	5
447	Fatigue in Patients with Lung Cancer Is Related with Accelerated Tryptophan Breakdown. PLoS ONE, 2012, 7, e36956.	1.1	32
448	Physical Activity and Sedentary Behavior of Cancer Survivors and Non-Cancer Individuals: Results from a National Survey. PLoS ONE, 2013, 8, e57598.	1.1	70
449	Myoelectrical Manifestation of Fatigue Less Prominent in Patients with Cancer Related Fatigue. PLoS ONE, 2013, 8, e83636.	1.1	27
450	Evidence of Significant Central Fatigue in Patients with Cancer-Related Fatigue during Repetitive Elbow Flexions till Perceived Exhaustion. PLoS ONE, 2014, 9, e115370.	1.1	27
451	Epoetin Alfa 60,000 U Once Weekly Followed by 120,000 U Every 3 Weeks Increases and Maintains Hemoglobin Levels in Anemic Cancer Patients Undergoing Chemotherapy. Oncologist, 2004, 9, 90-96.	1.9	34
452	Indolocarbazole derivatives “ a promising class of anticancer drugs. , 2019, 17, 20-26.	0.3	4
453	Exercise Recommendations for Cancer-Related Fatigue, Cognitive Impairment, Sleep Problems, Depression, Pain, Anxiety, and Physical Dysfunction“ A Review. Oncology & Hematology Review, 2012, 08, 81.	0.2	118
454	Electronic Patient-Reported Outcome Measures in Radiation Oncology: Initial Experience After Workflow Implementation. JMIR MHealth and UHealth, 2019, 7, e12345.	1.8	37
455	Beating Cancer-Related Fatigue With the Untire Mobile App: Protocol for a Waiting List Randomized Controlled Trial. JMIR Research Protocols, 2020, 9, e15969.	0.5	14
456	Psycho-oncology. Dialogues in Clinical Neuroscience, 2018, 20, 13-22.	1.8	52

#	ARTICLE	IF	CITATIONS
457	Negative impact of pretreatment anemia on local control after neoadjuvant chemoradiotherapy and surgery for rectal cancer. <i>Radiation Oncology Journal</i> , 2012, 30, 117.	0.7	13
458	A comprehensive review of head and neck cancer rehabilitation: Physical therapy perspectives. <i>Indian Journal of Palliative Care</i> , 2012, 18, 87.	1.0	49
459	Prevalence of fatigue among cancer patients receiving various anticancer therapies and its impact on Quality of Life: A cross-sectional study. <i>Indian Journal of Palliative Care</i> , 2012, 18, 165.	1.0	46
460	Fatigue and quality of life outcomes of palliative care consultation: A prospective, observational study in a tertiary cancer center. <i>Indian Journal of Palliative Care</i> , 2016, 22, 416.	1.0	7
461	Fatigue in cancer: A review of literature. <i>Indian Journal of Palliative Care</i> , 2009, 15, 19.	1.0	37
462	Evaluation and management of fatigue in oncology: A multidimensional approach. <i>Indian Journal of Palliative Care</i> , 2011, 17, 92.	1.0	7
463	Factors affecting quality of life and fatigue in patients with leukemia under chemotherapy. <i>Journal of Education and Health Promotion</i> , 2014, 3, 64.	0.3	17
464	Cancer related fatigue: A ubiquitous problem yet so under reported, under recognized and under treated. <i>South Asian Journal of Cancer</i> , 2015, 04, 021-023.	0.2	20
465	Implementing the Fatigue Guidelines at One NCCN Member Institution: Process and Outcomes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, 1092-1101.	2.3	55
466	Fatigue is the Most Important Symptom for Advanced Cancer Patients Who Have Had Chemotherapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 448-455.	2.3	149
467	Traditional Herbal Medicine, Sipjeondaebo-Tang, for Cancer-Related Fatigue: A Randomized, Placebo-Controlled, Preliminary Study. <i>Integrative Cancer Therapies</i> , 2021, 20, 153473542110408.	0.8	10
468	Mechanisms of apoptosis regulation and antiapoptotic action of oncogenic viruses. <i>Biopolymers and Cell</i> , 2000, 16, 455-467.	0.1	2
469	Impact of anemia on organ functions. , 2002, , 147-172.		1
470	Relationship between anemia, fatigue, and quality of life in cancer patients. , 2002, , 173-184.		1
471	Optimal level of hemoglobin in cancer patients. , 2002, , 369-390.		0
472	Effects of treatment with rhEPO on quality of life in anemic cancer patients. , 2002, , 405-424.		1
473	Systemic Support Therapy for Cancer Patients During and After Chemotherapy. , 2002, , 347-358.		0
475	Quality of life during chemotherapy : the role of anemia. <i>W Waves</i> , 2004, 10, 36-42.	0.0	3

#	ARTICLE	IF	CITATIONS
476	New Therapeutic Approaches to Myeloma. , 2004, , 319-353.		0
477	Hematopoietic Growth Factors in Lung Cancer. , 2004, , 249-274.		0
478	Tumorererschpfungssyndrom (Fatigue). , 2006, , 1305-1313.		0
480	Palliative Care in the Management of Cancer Pain. , 2007, , 360-375.		1
481	Relationship of hemoglobin, fatigue, and quality of life in anemic cancer patients. , 2008, , 369-391.		2
482	Impact of anemia and red blood cell transfusion on organ function. , 2008, , 317-367.		0
483	Recombinant human erythropoietin in pediatric oncology. , 2008, , 635-661.		0
484	Effects of rhEPO on quality of life in anemic cancer patients. , 2008, , 729-743.		0
487	Symptoms of anemia. , 2008, , 307-315.		1
488	Supportive Care for Older Cancer Patients. Translational Medicine Series, 2008, , 1-34.	0.0	0
489	Anemia and Red Cell Factors. Translational Medicine Series, 2008, , 1-20.	0.0	0
490	Komplementre Therapieverfahren. , 2009, , 215-268.		0
491	Treatment of fatigue in palliative care. , 2009, , 639-652.		0
492	Psychosocial Issues in Hepatocellular Carcinoma. , 2009, , 641-711.		1
493	Symptom Management in Children with Cancer. , 2009, , 1203-1253.		1
494	Cancer-Related Fatigue. , 2010, , 23-32.		2
495	Managing Symptoms over Time. , 2011, , 53-83.		0
497	Symptome in der Palliativmedizin. Springer-Lehrbuch, 2012, , 53-133.	0.1	0

#	ARTICLE	IF	CITATIONS
498	End-of-Life Care for Elderly Patients with Gynecologic Cancer. , 2013, , 367-390.		1
499	Fatigue-Syndrom als fundamentale Belastung. , 2013, , 71-76.		0
500	Apoptosis and Male Infertility. , 2013, , 217-229.		0
501	KomplementÄre Therapieverfahren. , 2014, , 261-316.		0
502	Disorders of Blood Cell Production in Clinical Oncology. , 2014, , 532-541.e10.		2
503	Recommendations for the Management of Cancer-Related Fatigue. , 2015, , 65-74.		1
504	Asthenia. , 2015, , 805-827.		0
505	Advances in Management of Complications for Head and Neck Cancer Therapy. , 2016, , 769-782.		2
506	Psychosocial Issues in Hepatocellular Carcinoma. , 2016, , 547-577.		0
507	Exercise Therapy and Fatigue Management. , 2019, , 395-401.		0
508	Symptome in der Palliativmedizin. , 2019, , 43-110.		0
509	Role of Chemokines and Chemokine Receptors in Infectious Diseases and Targeting Strategies. AAPS Advances in the Pharmaceutical Sciences Series, 2019, , 271-296.	0.2	0
510	Apoptosis and Male Infertility. , 2020, , 479-486.		2
514	Acupuncture for the Side Effects of Cancer Treatments. , 2008, , 201-211.		0
515	Cytokines in the Supportive Care of Cancer. , 2007, , 449-469.		0
516	Mindful Exercise, Quality of Life, and Cancer. , 2008, , 261-269.		0
517	Supportive Therapie mit Zytokinen. , 0, , 1405-1430.		0
518	KomplementÄre Therapieverfahren. , 2014, , 261-316.		0

#	ARTICLE	IF	CITATIONS
521	Quality of life and physicians' perception in myelodysplastic syndromes. American Journal of Blood Research, 2012, 2, 136-47.	0.6	37
524	Changes in daily activities of cancer patients after diagnosis: how do canadian and Iranian patients perceive the change?. Iranian Journal of Cancer Prevention, 2014, 7, 28-34.	0.7	2
526	Utilizing Multidimensional Computer Adaptive Testing to Mitigate Burden With Patient Reported Outcomes. AMIA ... Annual Symposium proceedings, 2015, 2015, 320-8.	0.2	20
528	What QLQ-C15-PAL Symptoms Matter Most for Overall Quality of Life in Patients With Advanced Cancer?. World Journal of Oncology, 2011, 2, 166-174.	0.6	3
529	Difference in Estimation of Side Effects of Chemotherapy between Physicians and Patients with Early-Stage Breast Cancer: The Use of Patient Reported Outcomes (PROs) in the Evaluation of Toxicity in Everyday Clinical Practice. Cancers, 2021, 13, 5922.	1.7	5
531	Defining routine fatigue care in Multiple Sclerosis in the United Kingdom: What treatments are offered and who gets them?. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732110722.	0.5	1
532	Effects of cognitive behavior therapy combined with Baduanjin in patients with colorectal cancer. World Journal of Gastrointestinal Oncology, 2022, 14, 319-333.	0.8	3
533	Risk factors associated with patient-reported fatigue among long-term oropharyngeal carcinoma survivors. Head and Neck, 2022, 44, 952-963.	0.9	2
534	Fatigue and quality of life among thyroid cancer survivors without persistent or recurrent disease. Endocrine Connections, 2022, 11, .	0.8	6
535	A Molecular Approach to Understanding the Role of Diet in Cancer-Related Fatigue: Challenges and Future Opportunities. Nutrients, 2022, 14, 1496.	1.7	5
537	Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review. Cancers, 2022, 14, 2470.	1.7	4
538	Cancer-Related Fatigue in Lung Cancer. , 2023, , 127-138.		0
539	Role of P-Selectin in the Development of Hemostasis Disorders in COVID-19. Biology Bulletin Reviews, 2022, 12, 406-413.	0.3	1
540	Sodium selenite inhibits proliferation and metastasis through ROS-mediated NF- $\kappa$ B signaling in renal cell carcinoma. BMC Cancer, 2022, 22, .	1.1	3
542	Management of Acute Toxicity. , 2022, , 209-218.		0
543	Effect and Mechanism of Cotrimoxazole Against Talaromyces marneffeii in vitro. Mycopathologia, 2022, 187, 579-593.	1.3	1
544	Effect of sex on psychological distress and fatigue over time in a prospective cohort of cancer survivors. Journal of Cancer Survivorship, 0, , .	1.5	0
545	Urinary Tract Infection: How It Happens?. European Medical Journal Urology, 0, , 62-67.	0.0	0

#	ARTICLE	IF	CITATIONS
546	A retrospective review on importance and various preparation of low molecular weight heparin for cardio vascular diseases. International Journal of Pharmaceutical Chemistry and Analysis, 2023, 9, 188-195.	0.1	0
547	Cancer Biology. , 2023, , 1-30.		0